Sofosbuvir & Ledipasvir Tablets Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 90 mg Ledipasvir / 400 mg Sofosbuvir
Reference Brands: Harvoni® (EU & US)
Category:
Hepatitis
Sofosbuvir & Ledipasvir Tablets (Harvoni®) are a once-daily oral treatment for chronic Hepatitis C infection. Combining 400 mg Sofosbuvir and 90 mg Ledipasvir, this FDA- and EMA-approved antiviral effectively stops viral replication. Widely used in the US and EU, it offers a safe, well-tolerated cure, making it essential for pharma B2B suppliers and healthcare providers targeting Hepatitis C management.
Sofosbuvir & Ledipasvir Tablets is available in Tablet
and strengths such as 90 mg Ledipasvir / 400 mg Sofosbuvir.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Sofosbuvir & Ledipasvir Tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Sofosbuvir & Ledipasvir Tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Sofosbuvir & Ledipasvir Tablets are a fixed-dose oral antiviral combination used to treat chronic Hepatitis C virus (HCV) infection. Marketed globally under the brand name Harvoni®, this potent direct-acting antiviral (DAA) therapy combines 90 mg Ledipasvir and 400 mg Sofosbuvir to inhibit viral replication. Approved by the US FDA and EMA, it offers a highly effective, once-daily regimen with excellent safety and tolerability profiles. Essential for pharma B2B suppliers and healthcare providers in the EU and US, Sofosbuvir & Ledipasvir supports global efforts to eliminate Hepatitis C through curative treatment options.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing